Human herpesvirus 8 (HHV-8) associated primary eVusion lymphomas arise and grow in the body cavities as eVusions, but it is not known whether the lining of body cavities and mesothelium derived malignancies are potential targets of HHV-8 infection. We examined a series of 13 diVuse malignant mesotheliomas and four mesothelial cell rich eVusion samples of non-neoplastic aetiology from nonimmunodepressed patients using the polymerase chain reaction to detect HHV-8 specific sequences. HHV-8 amplification products were absent in diVuse malignant mesotheliomas and in nonneoplastic eVusions samples. These results suggest that HHV-8 has a selective tropism among body cavity based tumours, being confined to primary effusion lymphomas. (J Clin Pathol: Mol Pathol 1998;51:113-114) Keywords: mesothelioma; primary eVusion lymphoma; human herpesvirus 8
Human herpesvirus 8 (HHV-8) DNA sequences have been isolated from Kaposi's sarcoma lesions and some lymphoproliferative disorders, including primary eVusion lymphoma, a rare high grade B cell lymphoma arising in the body cavities. [1] [2] [3] Recent studies suggest that HHV-8 might be more widespread than described originally, whereas other groups argue against this suggestion. 2 3 Thus, there is much interest about HHV-8 distribution in normal tissues, inflammatory conditions, and tumours. The restriction of HHV-8 to specific cell types and/or pathological entities suggests a role for this agent in the pathogenesis of HHV-8 associated diseases.
Regarding body cavity based tumours other than primary eVusion lymphomas, those of submesothelial origin do not harbour HHV-8 sequences. 4 5 To investigate whether HHV-8 infection is associated with mesothelial derived tumours, we tested a series of diVuse malignant mesotheliomas using the polymerase chain reaction (PCR) to amplify specific viral sequences. We also analysed DNA in mesothelial cell rich eVusion samples of non-neoplastic aetiology from non-immunodepressed patients.
Methods
A total of 20 samples was investigated for the presence of HHV-8 including: (1) serous eVusions (n = 3) and tissue samples (n = 10) from 13 patients aVected by histologically and immunophenotypically proved diVuse malignant mesothelioma; (2) serous eVusions (n = 4) obtained from individuals with nonneoplastic underlying diseases (cirrhosis and inflammatory conditions); and (3) skin biopsies (n = 3) from three non-human immunodeficiency virus (HIV) infected Italian patients with classic Kaposi's sarcoma (nodular lesions), as positive controls.
High molecular weight DNA was extracted from OCT frozen tissue samples (n = 10), DMSO frozen cell suspensions (n = 7), and paraYn wax embedded biopsies (n = 3) collected at diagnosis. DNA was obtained by cell lysis, proteinase K digestion, phenol/ chloroform extraction, and ethanol precipitation. The primers and PCR conditions used to amplify HHV-8 sequences have been reported elsewhere. 1 In all experiments, a positive control using DNA derived from one of the above mentioned Kaposi's sarcoma biopsies and a negative control (all reagents plus water and no DNA) were included. To verify the presence of amplifiable DNA, a 294 base pair fragment of the Bcl-6 first intron gene was also amplified in all cases. To determine the sensitivity of our assay, the DNA obtained from a Kaposi's sarcoma biopsy was diluted serially by mixing with DNA from non-HHV-8 infected normal lymphocytes. A specific amplification band could be visualised on the ethidium bromide stained agarose gel only at a 1/10 dilution of Kaposi's sarcoma DNA; no fragments were visible when 1/100 and 1/1000 dilutions were amplified. the patients had any clinical signs of immunodepression.
The mesothelial origin of tumour cells in diVuse malignant mesothelioma samples was determined by immunoperoxidase staining with monoclonal antibodies against cytokeratin, vimentin, Leu-M1(CD15), Ber-EP4, carcinoembryonic antigen, epithelial membrane antigen, and mesothelial cells (antibody HBME-1). Reactive and mesotheliomatous eVusions contained a variable number of CD5 positive lymphocytes (T cells) and CD68 positive cells (monocytes/macrophages), as well as cytokeratin/HBME-1 positive mesothelial cells.
PCR studies showed an absence of HHV-8 DNA sequences in all diVuse malignant mesothelioma samples and in all the nonneoplastic eVusions analysed, whereas HHV-8 DNA was amplified in the DNAs obtained from the three Kaposi's sarcoma biopsies. The HHV-8 amplification signals visualised after PCR in Kaposi's sarcoma DNAs were weak, in keeping with the finding that a low number of viral copies is usually detected in such samples. 6 
Discussion
Several studies investigating the presence of HHV-8 in tissues and diseases other than Kaposi's sarcoma, multicentric Castleman's disease, and primary eVusion lymphoma have reported conflicting observations. 2 3 HHV-8 DNA has been found in non-Kaposi's sarcoma skin lesions developing in post-transplant patients and non-Kaposi's sarcoma malignant vascular tumours. Other results argue against the presence of HHV-8 in endothelial Kaposi's sarcoma simulators or vascular lesions other than Kaposi's sarcoma and skin cancers of immunosuppressed patients; sporadic nonprimary eVusion lymphomas were found to harbour HHV-8 DNA. More recent studies have shown that HHV-8 may also infect a proportion of healthy adults. 3 7 This study indicates that HHV-8 is not present in diVuse malignant mesotheliomas and non-neoplastic eVusions containing mesothelial cells. Our PCR sensitivity allowed us to detect a 1/10 dilution of HHV-8 infected Kaposi's sarcoma DNA, a tumour in which low viral copy numbers are usually detected. 6 Therefore, our findings should also rule out the possibility of HHV-8 infection in diVuse malignant mesotheliomas with very low viral load. As to the suggestion that polymorphisms within the Kaposi's sarcoma Bam 330 region of the HHV-8 genome could contribute to false negative results, we believe that this is unlikely, although it cannot be formally ruled out. Although HHV-8 DNA sequences can be detected in some normal tissues and circulating lymphocytes, 2 3 the linings of body cavities are not targets for HHV-8 infection. Regarding body cavity based tumours, only primary eVusion lymphomas are found consistently to contain HHV-8 sequences. Two recent studies have reported the absence of detectable HHV-8 in primary vascular tumours of submesothelial origin. 4 5 Our findings extend these observations by showing that HHV-8 is absent in diVuse malignant mesothelioma, the only mesothelium derived malignancy related to body cavities. Thus, our study supports the view that the virus is distributed in a nonubiquitous manner, and is characteristically restricted to specific pathological entities. Except for primary eVusion lymphomas, HHV-8 does not seem to play an important pathogenetic role in any other tumour related to body cavities.
Molecular mimicry of human cytokines is a newly recognised characteristic of HHV-8, 8 which encodes homologues to multiple host cell genes including interleukin 6 (vIL-6). A common feature of some HHV-8 associated diseases is the upregulation of IL-6.
3 8 9 Interestingly, this characteristic is shared with diVuse malignant mesothelioma.
10 IL-6 is a growth factor for HHV-8 associated lesions, whereas its biological significance in diVuse malignant mesothelioma is unclear. It is not related to growth control mechanisms but is linked to systemic paraneoplastic events (fever, acute-phase reaction, cachexia, and thrombocytosis) associated with the disease.
10 Our study suggests indirectly that within the spectrum of IL-6 producing proliferative disorders, diVuse malignant mesotheliomas belong to a group lacking HHV-8 sequences and expressing human IL-6 (huIL-6). In contrast, other entities, such as primary eVusion lymphomas, contain HHV-8 DNA and express vIL-6.
8
The primary localisation of primary eVusion lymphomas in the serosal cavity might be because of the favourable conditions for the growth of HHV-8 infected circulating lymphocytes in this location, through huIL-6-mediated paracrine stimulation by mesothelial cells and vIL-6 mediated autocrine loops. Mutational analysis of this gene in aVected individuals identified a G to A transition resulting in an Arg to His amino acid substitution at residue 117. 3 It has been postulated that pancreatitis is caused by the inappropriate activation of pancreatic proenzymes. Trypsinogen is an inactive proenzyme for trypsin that is activated by the removal of the eight amino terminal amino acids. Normally, a small amount of active trypsin is present within the pancreas and, in general, it is inactivated rapidly by the pancreatic secretory trypsin inhibitor. Occasionally, when trypsin activity exceeds that of the pancreatic secretory trypsin inhibitor, a number of proenzymes are activated, such as mesotrypsin and enzyme Y. These enzymes are thought to be part of a feedback loop that inactivates trypsinogen and trypsin. x Ray crystal structure analysis, molecular modelling, and protein digestion data indicate that residue Arg 117 is a trypsin sensitive site, which can be cleaved by mesotrypsin and enzyme Y. The replacement of Arg 117 with His removes this putative fail-safe mechanism, leading to autodigestion of the pancreas and pancreatitis. 3 Here, we present the genetic analysis of a white hereditary pancreatitis family from the UK.
Methods

PATIENTS
Patients were from a five generation hereditary pancreatitis family that had 10 aVected members, demonstrated autosomal dominant inheritance, and originated from northern England (fig 1) .
ISOLATION OF GENOMIC DNA
Blood samples were obtained from five affected members of the family, individuals II:1, III:2, III:5, IV:2, and IV:6 (fig 1) , representing three generations of the family. Peripheral blood mononuclear cells were separated from 3 ml of whole blood and genomic DNA was extracted using the Gentra Systems Puregene DNA purification protocol (Gentra Systems, Minneapolis, USA), which is based on the salt precipitation method. A 911 base pair (bp) fragment containing exon 3 of the trypsinogen gene was amplified using PCR conditions described previously. 3 Briefly, PCR was carried out in a 25 µl reaction volume containing: 1× reaction buVer (50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100), 2.5 mM MgCl 2 , 200 µM dATP, dCTP, dGTP, dTTP, 10 pmols of the forward primer: dGGTCCTGGGTCTCATACCTT and 10 pmols of the reverse primer: dGGGTAG-GAGGCTTCACACTT, 1 unit of Taq DNA polymerase (Promega, Southampton, UK), and 100 ng genomic DNA. The PCR amplification was carried out under the following conditions: 95°C for five minutes, then 40 cycles of 95°C for one minute, 64°C for one minute, and 72°C for two minutes, followed by a final extension step at 72°C for 10 minutes. The PCR products (10 µl aliquots) were analysed on a 1.5% agarose gel stained with ethidium bromide.
RESTRICTION ENZYME DIGESTION
The G to A mutation at residue 117 of the trypsinogen gene creates a restriction site recognised by the enzyme AflIII. The amplified PCR products were digested overnight at 37°C with AflIII according to the manufacturer's instructions (New England Biolabs, Hitchin, Hertfordshire, UK). The restriction digestion products (10 µl aliquots) were analysed on a 1.5% agarose gel stained with ethidium bromide.
SEQUENCE ANALYSIS OF PCR PRODUCTS
The PCR product was desalted and separated from unincorporated nucleotides and primers using a Microcon 100 column (Amicon, Beverley, USA). The concentrated template (1 µl) was sequenced with an internal primer, 3 dTGACCCACATCCCTCTG, using a PRISM ready reaction terminator cycle sequencing kit (Applied Biosystems, Warrington, Cheshire, UK) on an automated fluorescence DNA sequencer (Applied Biosystems 377).
Results
The trypsinogen gene was amplified from five aVected family members and an unaVected control. Restriction enzyme digestion of the PCR products using the restriction enzyme AflIII found that all five aVected family members were heterozygous for the presence of the restriction enzyme site (fig 2) . The enzyme AflIII recognises the restriction enzyme site 5'AwCGTGT 3', which is created by a G to A base pair mutation in the trypsinogen gene. Three bands were seen in the aVected individuals: a large band (911 bp) and two smaller bands (565 bp and 346 bp); only the large 911 bp band was seen in the unaVected control. The large band represents the normal allele and the two smaller bands represent the mutant allele, indicating that the G to A mutation is present in the five aVected individuals examined, but not the normal control. The PCR amplifications and restriction enzyme digestions were repeated to confirm the results obtained. DNA sequencing of the PCR product from the common ancestor (II:2) confirmed the presence of the G to A mutation. This G to A transition results in an amino acid substitution of arginine (CGC) for histidine (CAC) at residue 117 of the trypsinogen gene.
Discussion
This study describes the identification of a G to A mutation at residue 117 of the cationic trypsinogen gene in a UK hereditary pancreatitis family from Yorkshire. Our study is the first to confirm the involvement of the cationic trypsinogen gene in hereditary pancreatitis. One hundred hereditary pancreatitis kindreds have been reported worldwide; most of the families are white, although other ethnic groups have been identified. 4 Previously, this G to A mutation has been identified in five hereditary pancreatitis kindreds, four from the USA and one from Italy. One hundred and forty unaVected individuals were also screened for the AflIII restriction enzyme site to determine that this was not a polymorphism. Initially, the presence of the same mutation in five diVerent families was thought to be the result of a common ancestor. Haplotype analysis of the USA families did identify a common 4cM region associated with the hereditary pancreatitis phenotype, indicating that these families are distantly related. Our family from northern England could be distantly related to the USA families, which have English ancestry. However, the Italian family from Naples had a unique haplotype, suggesting that the same mutation has oc- 
